SUMO1/sentrin Specific Protease 6 (SENP6) Peptide
-
- Target See all SENP6 products
- SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-SENP6 antibody (Catalog #: ARP50600_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))
- Synonyms
- SSP1 Peptide, SUSP1 Peptide, 2810017C20Rik Peptide, E130319N12Rik Peptide, Susp1 Peptide, mKIAA0797 Peptide, fc83h02 Peptide, im:7148342 Peptide, wu:fc83h02 Peptide, zgc:171230 Peptide, SUMO1/sentrin specific peptidase 6 Peptide, SUMO/sentrin specific peptidase 6 Peptide, SUMO1/sentrin specific peptidase 6a Peptide, SENP6 Peptide, Senp6 Peptide, senp6a Peptide
- Background
-
SENP6 is a UBL-specific protease that deconjugates SUMO1, SUMO2 and SUMO3 from targeted proteins. It does not seem to be involved in the processing of full-length SUMO proteins to their mature forms. SENP6 deconjugates SUMO1 from RXRA, leading to transcriptional activation. It may act preferentially on substrates containing 3 or more SUMO2 or SUMO3 moieties.Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1, MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA, MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM].
Alias Symbols: FLJ11355, FLJ11887, KIAA0389, KIAA0797, SSP1, SUSP1
Protein Interaction Partner: ARNT,SUMO1
Protein Size: 1105 - Molecular Weight
- 125 kDa
- Gene ID
- 26054
- NCBI Accession
- NM_001100409, NP_001093879
- UniProt
- Q9GZR1
-